Cyclophosphamide Sandoz
Alkylating chemotherapy agent – solution for injection/infusion
Cyclophosphamide Sandoz is an alkylating chemotherapy agent used to treat various cancers and severe autoimmune conditions. It works by cross-linking DNA strands in rapidly dividing cells, preventing their growth and replication. This medication is administered as a 100 mg/ml solution for injection or infusion under specialist oncology supervision. As a potent cytotoxic drug, cyclophosphamide requires careful monitoring of blood counts, kidney function, and hydration status throughout treatment.
Quick Facts
Key Takeaways
- Cyclophosphamide Sandoz is a powerful alkylating chemotherapy agent used for multiple cancer types and severe autoimmune diseases, administered under specialist supervision only.
- Regular blood count monitoring is essential during treatment as cyclophosphamide causes significant bone marrow suppression, increasing the risk of infections and bleeding.
- Adequate hydration and mesna prophylaxis are critical to prevent hemorrhagic cystitis, a characteristic and potentially serious side effect of cyclophosphamide therapy.
- Cyclophosphamide is teratogenic and can impair fertility in both men and women – fertility preservation should be discussed before starting treatment.
- Drug interactions are numerous and clinically significant; always inform your oncologist about all medications, supplements, and herbal products you are taking.
What Is Cyclophosphamide Sandoz and What Is It Used For?
Cyclophosphamide belongs to the nitrogen mustard family of alkylating agents and has been a cornerstone of cancer chemotherapy since its development in the 1950s. It is classified as a prodrug, meaning it is inactive when first administered and must be converted into its active metabolites by liver enzymes (specifically the cytochrome P450 system) to exert its anticancer effects. The two key active metabolites are phosphoramide mustard, which cross-links DNA strands and prevents cell division, and acrolein, which is responsible for the drug's bladder toxicity.
Cyclophosphamide Sandoz is supplied as a 100 mg/ml solution for injection or infusion, allowing for precise dosing based on the patient's body surface area and clinical condition. The solution formulation eliminates the need for reconstitution, providing convenience and reducing preparation errors in clinical settings. It is typically administered as an intravenous infusion in a hospital or outpatient oncology clinic, though cyclophosphamide is also available in oral tablet form for certain indications and maintenance regimens.
Oncology Indications
In oncology, cyclophosphamide is used as part of combination chemotherapy regimens for a wide range of malignancies. Its broad spectrum of activity makes it one of the most versatile chemotherapy agents available. Key cancer indications include:
- Non-Hodgkin lymphoma (NHL) – A major component of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and R-CHOP regimens, which are the standard first-line treatments for diffuse large B-cell lymphoma and other aggressive NHLs.
- Hodgkin lymphoma – Used in BEACOPP and other salvage regimens for relapsed or refractory disease.
- Chronic lymphocytic leukemia (CLL) – Part of the FC (fludarabine/cyclophosphamide) and FCR regimens.
- Breast cancer – An essential component of AC (doxorubicin/cyclophosphamide), TC (docetaxel/cyclophosphamide), and CMF (cyclophosphamide/methotrexate/5-fluorouracil) regimens used in both adjuvant and neoadjuvant settings.
- Ovarian cancer – Used in combination with platinum-based agents as an alternative to paclitaxel-based regimens.
- Small cell lung cancer – Part of combination chemotherapy regimens, particularly in the relapsed setting.
- Multiple myeloma – Used in various combination regimens including VCD (bortezomib/cyclophosphamide/dexamethasone).
- Neuroblastoma and other pediatric solid tumors – A key agent in many pediatric oncology protocols.
Immunosuppressive Indications
At lower doses, cyclophosphamide has potent immunosuppressive properties and is used for the treatment of severe, life-threatening autoimmune conditions that have not responded to less toxic therapies. The immunosuppressive effect is mediated through selective depletion of B lymphocytes and modulation of T cell responses. Important autoimmune indications include:
- Lupus nephritis – Used as induction therapy for severe (class III-V) lupus nephritis, typically in the Euro-Lupus low-dose protocol or the NIH high-dose protocol.
- Granulomatosis with polyangiitis (GPA) – Previously known as Wegener's granulomatosis, cyclophosphamide combined with corticosteroids remains a standard induction regimen for severe disease with organ-threatening manifestations.
- Microscopic polyangiitis (MPA) – Similar to GPA, cyclophosphamide is used for induction of remission in severe ANCA-associated vasculitis.
- Severe systemic sclerosis – Used for progressive interstitial lung disease associated with scleroderma.
Conditioning Before Transplantation
High-dose cyclophosphamide is a critical component of conditioning regimens used before hematopoietic stem cell transplantation (HSCT). The drug serves dual purposes in this setting: it provides potent myeloablation to create space in the bone marrow for donor cells, and it delivers strong immunosuppression to prevent graft rejection. Common conditioning regimens include cyclophosphamide combined with total body irradiation (Cy/TBI) or busulfan (Bu/Cy). These high-dose regimens require extensive supportive care and careful monitoring in specialized transplant units.
What Should You Know Before Taking Cyclophosphamide Sandoz?
Cyclophosphamide is a potent cytotoxic agent with a significant side effect profile, and careful patient selection and pre-treatment evaluation are essential. Your oncologist or rheumatologist will conduct a thorough assessment before initiating treatment, including comprehensive blood work, organ function tests, and a detailed medication history. It is critical that you provide your healthcare team with a complete list of all medications, including over-the-counter drugs, herbal supplements, and vitamins, as cyclophosphamide has numerous clinically important drug interactions.
Contraindications
- Known hypersensitivity to cyclophosphamide or any of its excipients
- Severe bone marrow suppression (aplasia), particularly if due to prior chemotherapy or radiotherapy
- Active severe infection (including active urinary tract infection)
- Urinary tract obstruction or urinary outflow obstruction
- Active hemorrhagic cystitis
- Pregnancy or breastfeeding
Warnings and Precautions
Several important precautions must be observed during cyclophosphamide treatment. The drug carries risks of serious and potentially life-threatening toxicities that require ongoing monitoring and proactive management:
- Myelosuppression: Cyclophosphamide causes dose-dependent suppression of blood cell production. The nadir (lowest point) of white blood cells typically occurs 7–14 days after administration, with recovery by days 21–28. Complete blood counts must be monitored at least weekly during treatment. Treatment should be delayed or dose-reduced if the neutrophil count falls below acceptable thresholds.
- Immunosuppression and infections: The profound immunosuppressive effect significantly increases vulnerability to bacterial, viral, fungal, and opportunistic infections. Patients may require prophylactic antimicrobials, and live vaccines are strictly contraindicated during treatment and for a period after cessation.
- Hemorrhagic cystitis: Acrolein, a toxic metabolite of cyclophosphamide, is excreted in urine and can cause inflammation and bleeding of the bladder lining. Prevention requires vigorous intravenous hydration before, during, and after cyclophosphamide administration, along with mesna (2-mercaptoethane sulfonate sodium), which binds and neutralizes acrolein in the urinary tract.
- Cardiotoxicity: High-dose cyclophosphamide (particularly doses exceeding 150 mg/kg over 4 days, as used in transplant conditioning) can cause acute cardiac toxicity including hemorrhagic myocarditis, pericardial effusion, and heart failure. Cardiac function should be assessed before high-dose treatment.
- Secondary malignancies: Long-term use of cyclophosphamide is associated with an increased risk of secondary cancers, particularly bladder cancer, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML). The risk is cumulative and dose-dependent.
- Pulmonary toxicity: Interstitial pneumonitis and pulmonary fibrosis can occur, though less commonly. Patients should report any new or worsening respiratory symptoms promptly.
- Hepatotoxicity: Veno-occlusive disease (sinusoidal obstruction syndrome) of the liver can occur, particularly with high-dose regimens. Liver function should be monitored regularly.
Pregnancy and Breastfeeding
Cyclophosphamide is classified as FDA Pregnancy Category D and is absolutely contraindicated during pregnancy. The drug is teratogenic and embryotoxic, causing malformations including limb defects, craniofacial abnormalities, and growth restriction when exposure occurs during pregnancy.
- Women of childbearing potential must use highly effective contraception during treatment and for at least 12 months after the last dose.
- Men must use effective contraception during treatment and for at least 6 months after the last dose.
- Breastfeeding is contraindicated during treatment as cyclophosphamide and its metabolites are excreted in breast milk.
- Fertility impact: Cyclophosphamide can cause premature ovarian failure in women (especially at cumulative doses >7.5 g/m² and in older patients) and oligospermia or azoospermia in men. Fertility preservation options (sperm banking, egg/embryo freezing, ovarian tissue cryopreservation) should be discussed before treatment initiation.
How Does Cyclophosphamide Sandoz Interact with Other Drugs?
Cyclophosphamide is a prodrug that requires activation by hepatic cytochrome P450 enzymes (primarily CYP2B6, CYP3A4, and CYP2C9). Any drug that affects these enzymes can change how quickly cyclophosphamide is activated, potentially increasing toxicity or reducing effectiveness. Additionally, cyclophosphamide itself can alter the metabolism and effects of many other drugs. The interaction profile is complex and requires careful management by the treating physician and clinical pharmacist.
Major Interactions
| Drug/Class | Interaction Effect | Clinical Significance |
|---|---|---|
| Live vaccines (MMR, varicella, BCG, etc.) | Risk of disseminated vaccine infection due to immunosuppression | Contraindicated during and for 3–6 months after treatment |
| Anthracyclines (doxorubicin, epirubicin) | Additive cardiotoxicity; increased risk of heart failure | Monitor cardiac function; cumulative dose limits apply |
| Allopurinol | Increased myelosuppression via inhibition of cyclophosphamide metabolism | Dose reduction may be needed; monitor blood counts closely |
| Succinylcholine | Prolonged neuromuscular blockade due to reduced cholinesterase activity | Alert anesthesiologist before any surgical procedure |
| Warfarin | Enhanced or diminished anticoagulant effect; unpredictable | Monitor INR frequently; dose adjustment likely needed |
| Phenobarbital / Phenytoin / Rifampicin | CYP enzyme induction increases cyclophosphamide activation | May increase both efficacy and toxicity; close monitoring required |
Minor Interactions
Several additional interactions are clinically noteworthy, though typically more manageable than the major interactions listed above:
- ACE inhibitors – May increase the risk of leukopenia when used concurrently with cyclophosphamide. Blood counts should be monitored more frequently.
- Thiazide diuretics – May prolong cyclophosphamide-induced leukopenia by reducing renal clearance of active metabolites.
- Grapefruit juice – Inhibits CYP3A4, potentially altering cyclophosphamide metabolism. Patients should avoid grapefruit products during treatment.
- Digoxin (tablets) – Cyclophosphamide may reduce absorption of digoxin tablets. Digoxin levels should be monitored and liquid formulations may be preferred.
- Ciclosporin – Reduced ciclosporin serum concentrations may occur. Monitor ciclosporin levels and adjust dose accordingly.
- Insulin and oral antidiabetics – Cyclophosphamide may potentiate the hypoglycemic effect of these agents. Blood glucose monitoring should be intensified.
Always inform your oncologist, pharmacist, and any other treating physicians that you are taking cyclophosphamide. This includes before any surgical procedure, dental work, or emergency treatment. Keep an up-to-date medication list and carry it with you at all times. Do not start any new medication, including over-the-counter drugs and supplements, without first consulting your oncology team.
What Is the Correct Dosage of Cyclophosphamide Sandoz?
Cyclophosphamide Sandoz 100 mg/ml solution is dosed according to established treatment protocols for each specific indication. Dosing is almost always calculated based on the patient's body surface area (BSA), which is determined from height and weight measurements. The treating oncologist or rheumatologist will adjust the dose based on individual patient factors including renal function, hepatic function, prior treatments, current blood counts, and overall performance status. The information below represents typical dosing ranges from standard protocols and should not be used for self-administration or dose adjustments.
Adults
| Indication | Typical Dose | Schedule |
|---|---|---|
| NHL (CHOP/R-CHOP) | 750 mg/m² IV | Day 1 of each 21-day cycle, 6–8 cycles |
| Breast cancer (AC) | 600 mg/m² IV | Day 1 of each 21-day cycle, 4 cycles |
| CLL (FC/FCR) | 250 mg/m² IV daily | Days 1–3 of each 28-day cycle, 6 cycles |
| Lupus nephritis (Euro-Lupus) | 500 mg IV (fixed dose) | Every 2 weeks for 6 doses |
| ANCA vasculitis | 15 mg/kg IV (max 1.2 g) | Every 2–3 weeks for 3–6 months |
| HSCT conditioning | 60 mg/kg/day IV | Days −3 and −2 before transplant |
Children
Pediatric dosing of cyclophosphamide varies significantly depending on the diagnosis, treatment protocol, and the child's age, weight, and body surface area. All pediatric oncology protocols are managed by specialized pediatric oncologists in tertiary care centers. Dosing for children under 12 months of age is typically calculated based on body weight rather than body surface area to ensure accuracy. Common pediatric indications include neuroblastoma, Wilms tumor, rhabdomyosarcoma, non-Hodgkin lymphoma, and acute lymphoblastic leukemia. Doses range from 300–1800 mg/m² depending on the specific protocol being used.
Elderly
Elderly patients (typically defined as over 65 years) may be at increased risk of cyclophosphamide-related toxicity due to age-related decline in renal function, hepatic metabolism, and bone marrow reserve. Dose reductions of 25–50% may be necessary, and more frequent blood count monitoring is recommended. Cardiac function should be carefully assessed before treatment, particularly when cyclophosphamide is combined with anthracyclines. The choice of chemotherapy regimen and dose intensity should be guided by comprehensive geriatric assessment and the patient's overall fitness and comorbidities.
Renal Impairment
Dose adjustment is recommended for patients with significant renal impairment. While cyclophosphamide itself is primarily metabolized by the liver, its active metabolites are partially excreted by the kidneys. In patients with a creatinine clearance below 10 ml/min, a dose reduction of 25% is generally recommended. Hemodialysis removes cyclophosphamide and its metabolites, so administration should be timed appropriately in relation to dialysis sessions.
Missed Dose
Cyclophosphamide is administered in a clinical setting by healthcare professionals, so missed doses are managed by the treating team. If a scheduled treatment session is delayed due to low blood counts, infection, or other complications, the oncologist will determine the appropriate timing for the next dose. Treatment delays of 1–2 weeks are common and are preferable to administering the drug when blood counts have not recovered sufficiently.
Overdose
There is no specific antidote for cyclophosphamide overdose. Overdose can result in severe, life-threatening myelosuppression, hemorrhagic cystitis, cardiotoxicity, and multi-organ failure. Management is supportive and may include:
- Aggressive intravenous hydration and mesna administration to protect the bladder
- Granulocyte colony-stimulating factor (G-CSF) support for severe neutropenia
- Platelet and red blood cell transfusions as needed
- Broad-spectrum antimicrobial prophylaxis and treatment of infections
- Hemodialysis may help remove the drug and its metabolites
- Intensive care unit monitoring for cardiac and multi-organ complications
If you suspect an overdose, contact your oncology team or emergency services immediately.
What Are the Side Effects of Cyclophosphamide Sandoz?
Like all cytotoxic chemotherapy agents, cyclophosphamide affects rapidly dividing cells throughout the body, not just cancer cells. This results in a predictable pattern of side effects that correlate with the tissues most affected: bone marrow (blood cell production), gastrointestinal mucosa, hair follicles, and the immune system. The severity and incidence of side effects depend on the dose, treatment schedule, duration of therapy, and individual patient factors. Your oncology team will provide comprehensive supportive care to manage these effects and maintain your quality of life during treatment.
Very Common (>1 in 10 patients)
These side effects affect more than 10% of patients
- Myelosuppression – Leukopenia (low white blood cells), neutropenia, thrombocytopenia (low platelets), anemia
- Nausea and vomiting – Usually occurs 6–12 hours after administration; highly emetogenic at higher doses
- Alopecia (hair loss) – Occurs in 40–60% of patients; usually reversible after treatment completion
- Fatigue and general malaise
- Immunosuppression and increased susceptibility to infections
- Mucositis (mouth sores) and stomatitis
- Loss of appetite (anorexia)
Common (1 in 10 to 1 in 100 patients)
These side effects affect 1–10% of patients
- Hemorrhagic cystitis – Bladder inflammation with bloody urine; prevented by hydration and mesna
- Diarrhea or constipation
- Hepatotoxicity – Elevated liver enzymes
- Skin rash and dermatitis
- Nail changes – Discoloration, ridging, or nail loss
- Febrile neutropenia – Fever during low white blood cell counts (medical emergency)
- Electrolyte disturbances – Including hyponatremia (low sodium)
Uncommon (1 in 100 to 1 in 1,000 patients)
These side effects affect 0.1–1% of patients
- Cardiotoxicity – Heart failure, myocarditis, pericarditis (especially with high doses)
- Pulmonary toxicity – Interstitial pneumonitis, pulmonary fibrosis
- SIADH (syndrome of inappropriate antidiuretic hormone) – Water retention, hyponatremia
- Veno-occlusive disease of the liver (sinusoidal obstruction syndrome)
- Peripheral neuropathy
- Gonadal toxicity – Premature ovarian failure, azoospermia
Rare (<1 in 1,000 patients)
These side effects affect fewer than 0.1% of patients
- Secondary malignancies – Bladder cancer, MDS, acute myeloid leukemia (with prolonged use)
- Severe anaphylactic reactions
- Toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome
- Rhabdomyolysis
- Disseminated intravascular coagulation (DIC)
- Renal tubular necrosis
Contact your oncology team or go to the emergency department immediately if you experience any of the following during or after cyclophosphamide treatment:
- Fever above 38°C (100.4°F), especially if your white blood cell counts are low
- Blood in your urine (pink, red, or brown discoloration)
- Severe or persistent vomiting preventing fluid intake
- Unusual bleeding or bruising
- Signs of infection: chills, sore throat, cough, painful urination
- Shortness of breath or difficulty breathing
- Chest pain or irregular heartbeat
- Severe abdominal pain
How Should You Store Cyclophosphamide Sandoz?
Cyclophosphamide Sandoz 100 mg/ml solution for injection/infusion is a cytotoxic medication that requires specific storage conditions to maintain its stability and safety. In practice, this medication is stored and handled exclusively in hospital pharmacies and oncology treatment facilities, not in the home setting. Patients receiving cyclophosphamide do not typically handle or store the medication themselves.
- Temperature: Store in a refrigerator at 2–8°C. Do not freeze.
- Light protection: Keep the vials in the outer carton to protect from light.
- After opening: The product should be used immediately after opening. Refer to the product's Summary of Product Characteristics for specific stability data on diluted solutions.
- Handling precautions: Cyclophosphamide is a cytotoxic agent. It must be prepared and handled by trained personnel using appropriate personal protective equipment (gloves, gowns, eye protection) in a designated area, ideally a biological safety cabinet.
- Disposal: Any unused product, contaminated materials, and empty containers must be disposed of according to local requirements for cytotoxic waste.
- Spill management: In case of accidental spillage, the area must be cleaned immediately by trained personnel using established cytotoxic spill procedures.
You will not be required to store or handle cyclophosphamide at home. The solution formulation is administered in hospital or clinic settings by trained healthcare professionals. If your doctor prescribes oral cyclophosphamide tablets for home use, follow the specific storage instructions on the tablet packaging: store below 25°C in the original container, and keep the medication out of reach of children and away from food.
What Does Cyclophosphamide Sandoz Contain?
Cyclophosphamide Sandoz 100 mg/ml solution for injection/infusion is a ready-to-use sterile formulation designed for intravenous administration. Understanding the composition of your medication is important, particularly if you have known allergies or sensitivities to any pharmaceutical excipients.
Active Ingredient
- Cyclophosphamide monohydrate – equivalent to 100 mg cyclophosphamide per ml of solution. Cyclophosphamide (chemical name: 2-[bis(2-chloroethyl)amino]-1,3,2-oxazaphosphinan-2-oxide; molecular formula: C7H15Cl2N2O2P) is a synthetic alkylating agent derived from nitrogen mustard. It is a white crystalline powder that is freely soluble in water.
Excipients
The solution formulation typically contains:
- Water for injections – Purified solvent forming the base of the solution
The exact excipient composition may vary by batch and specific product authorization. Always refer to the manufacturer's product information leaflet for the complete and most up-to-date list of excipients. If you have known allergies to any pharmaceutical ingredients, discuss this with your oncologist or pharmacist before treatment begins.
Pharmaceutical Form
Cyclophosphamide Sandoz is supplied as a clear, colorless to slightly yellow solution for injection or infusion. Each vial contains a specific volume of solution at a concentration of 100 mg/ml. The solution can be further diluted with 0.9% sodium chloride solution or 5% glucose solution for intravenous infusion, according to the prescribing instructions.
Frequently Asked Questions
Medical References & Sources
This article is based on the following peer-reviewed sources and international guidelines:
- European Medicines Agency (EMA). Cyclophosphamide – Summary of Product Characteristics. EMA, 2024.
- U.S. Food and Drug Administration (FDA). Cyclophosphamide FDA Label. Updated 2023.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. WHO, 2023. Cyclophosphamide listed as an essential anticancer agent.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 5.2024.
- Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-2131.
- De Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670-680.
- British National Formulary (BNF). Cyclophosphamide. NICE/BNF, 2025.
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO, 2024.
- Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6(11):638-647.
- Bernatsky S, Clarke AE, Bhatt D, et al. Malignancy risk in systemic lupus erythematosus. Lupus. 2023;32(1):7-14.
About Our Medical Editorial Team
This article was written and reviewed by iMedic's medical editorial team, which includes board-certified specialists in oncology, hematology, clinical pharmacology, and rheumatology. Our content follows the GRADE evidence framework and adheres to the highest standards of medical accuracy.
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog. Read more
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in oncology, hematology, clinical pharmacology, and rheumatology.